Daiichi Sankyo says its underlying business remains strong despite a one time expense and conservative earnings guidance that came in below market expectations. The Japanese drugmaker reported double digit growth and rising revenue, supported by robust demand for its flagship cancer treatments.
The company also outlined its medium term outlook, highlighting antibody drug conjugates, research investment and the role of artificial intelligence, even as competition intensifies and currency moves remain a factor. Hiroyuki Okuzawa, President and CEO of Daiichi Sankyo, spoke exclusively with Shery Ahn on Insight with Haslinda Amin about results, strategy and growth priorities.
Bloomberg videos, provided by MT Newswires
